LONDON and PHILADELPHIA – July [6], 2026 – Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director.
Dr. Vink serves as Chairman at Arch Biopartners Inc (TSXV:ARCH, OTCQB:ACHFF) and on the board of Spero Therapeutics Inc. (NASDAQ:SPRO) as Nominating and Corporate Governance Chair. He is also Chairman of three privately held companies, Micreos Group (Bilthoven, Netherlands), Secura Bio Inc. (Boston, USA), and F2G Ltd (Manchester, UK), and is a senior advisor to Athyrium Capital Management LP (New York, USA) and Forbion Ventures (Naarden, Netherlands).
Christina Coughlin, CEO of Avacta commented:
“We are delighted to welcome Patrick to the Board of Directors of Avacta. His appointment adds considerable sector experience in Pharma financing, operations and partnering, having worked for a number of European and US companies, both private and listed businesses. His extensive experience and expertise in building companies comes at a key time for Avacta as we advance our pipeline, based on our proprietary pre|CISION® platform which brings unique potential advantages to cancer patients, and continue constructive partnership discussions across our assets.”
Patrick Vink, Deputy Chairman of Avacta, added:
“I am excited to join the Board at Avacta at this important time for the company. Avacta’s pre|CISION® technology has the potential to change the way that the field thinks about cancer therapy. The upcoming data, including first clinical results from the Gen Two product AVA6103, could be transformative for Avacta and I look forward to working with management and my fellow directors to lead the company on the journey ahead.”
Previously, Dr. Vink served as Executive Vice-President and Chief Operating Officer at Cubist Pharmaceuticals Inc., a leader in the anti-infective and acute care hospital market. He oversaw all worldwide commercial and technical operations as well as managing the company’s P&L until the successful acquisition of Cubist by Merck. He joined Cubist in 2012 as Senior Vice President and Head of International Business Operations having started his career at Sanofi and held senior executive roles at Biogen, Sandoz, and Mylan.
Dr. Vink served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his MBA in 1992 at the University of Rochester.